--Health Plan Adopts Groundbreaking Cancer
Detection Technology for Members in California and North
Carolina--
GRAIL, LLC, a healthcare company whose mission is to detect
cancer early when it can be cured, announced today a partnership
with Alignment Health Plan, a national Medicare Advantage health
plan from Alignment Healthcare (NASDAQ: ALHC), to provide its
Medicare Advantage members access to Galleri®, GRAIL’s
groundbreaking multi-cancer early detection blood test. Based in
Orange, California, Alignment Health Plan is the first Medicare
Advantage plan to offer the Galleri test as a complement to
recommended single cancer screenings.
“Providing innovative benefits to support the health and care
needs of our members is what we do here at Alignment,” said Dawn
Maroney, markets president, Alignment Healthcare, and CEO,
Alignment Health Plan (CA). “Taking preventive measures before
signs and symptoms appear is key to finding cancer early when it is
most treatable. We are excited to partner with GRAIL to provide
seniors the tools they need to proactively manage their
health.”
New and existing Alignment Health Plan members who enroll in
select HMO and PPO plans in California and North Carolina1 will
have access to Galleri beginning Jan. 1, 2022. Galleri is available
by prescription only.
“GRAIL is thrilled to partner with Alignment Health Plan to
offer our first-of-its-kind Galleri test to a population that by
age alone has an elevated risk of developing cancer,” said Dr. Josh
Ofman, president and chief medical officer at GRAIL. “Providing
access to a technology that can detect cancer signals in the blood,
even before symptoms appear, can help us decrease the burden of
late-stage cancer diagnoses. We commend Alignment for its
innovative and proactive approach to early cancer detection for
Medicare Advantage members.”
In a clinical study, Galleri demonstrated the ability to detect
more than 50 types of cancer, over 45 of which lack recommended
screening tests today, with a low false positive rate of less than
1%. When cancer is detected, Galleri can determine the cancer
signal origin with high accuracy.
More than 600,000 people died from cancer last year in the
United States, according to the American Cancer Society. This is in
large part because the majority of cancers are found too late when
outcomes are often poor. Recommended screening tests save lives,
but only cover five cancer types in the U.S.: breast, colon,
cervical, prostate, and (in high-risk adults) lung. In fact, about
seven in ten cancer deaths have no recommended early detection
screening.
About Galleri
The earlier that cancer is detected, the higher the chance of
successful outcomes. The Galleri multi-cancer early detection test
can detect more than 50 types of cancer, as defined by the American
Joint Committee on Cancer Staging Manual, through a routine blood
draw. When a cancer signal is detected, the Galleri test predicts
the cancer signal origin, or where the cancer is located in the
body, with high accuracy to help guide the next steps to diagnosis.
The Galleri test requires a prescription from a licensed healthcare
provider and should be used in addition to recommended cancer
screenings such as mammography, colonoscopy, prostate-specific
antigen (PSA) test, or cervical cancer screening. It is intended
for use in people with an elevated risk of cancer, such as those
aged 50 or older.
For more information about Galleri, visit www.galleri.com.
About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer
early, when it can be cured. GRAIL is focused on alleviating the
global burden of cancer by developing pioneering technology to
detect and identify multiple deadly cancer types early. The company
is using the power of next-generation sequencing, population-scale
clinical studies, and state-of-the-art computer science and data
science to enhance the scientific understanding of cancer biology,
and to develop its multi-cancer early detection blood test. GRAIL
is headquartered in Menlo Park, CA with locations in Washington,
D.C., North Carolina, and the United Kingdom. GRAIL, LLC, is a
wholly-owned subsidiary of Illumina, Inc. (NASDAQ:ILMN). For more
information, please visit www.grail.com.
About Alignment Healthcare
Alignment Healthcare is a consumer-centric platform delivering
customized health care in the United States to seniors and those
who need it most, the chronically ill and frail, through its
Medicare Advantage plans. Alignment Healthcare provides partners
and patients with customized care and service where they need it
and when they need it, including clinical coordination, risk
management and technology facilitation. Alignment Healthcare offers
health plan options through Alignment Health Plan and also partners
with select health plans to help deliver better benefits at lower
costs.
Important Galleri Safety Information
Galleri is recommended for use in adults with an elevated risk
for cancer, such as those aged 50 or older. The Galleri test does
not detect all cancers and should be used in addition to routine
cancer screening tests recommended by a healthcare provider.
Galleri is intended to detect cancer signals and predict where in
the body the cancer signal is located.
Results should be interpreted by a healthcare provider in the
context of medical history, clinical signs, and symptoms. A test
result of “Cancer Signal Not Detected” does not rule out cancer. A
test result of “Cancer Signal Detected” requires confirmatory
diagnostic evaluation by medically established procedures (e.g.,
imaging) to confirm cancer.
If cancer is not confirmed with further testing, it could mean
that cancer is not present or testing was insufficient to detect
cancer, including due to the cancer being located in a different
part of the body. False positive (a cancer signal detected when
cancer is not present) and false negative (a cancer signal not
detected when cancer is present) test results do occur. Galleri is
prescription only.
Laboratory/Test Information
GRAIL’s clinical laboratory is certified under the Clinical
Laboratory Improvement Amendments of 1988 (CLIA) and accredited by
the College of American Pathologists. The Galleri test was
developed, and its performance characteristics were determined by
GRAIL. The Galleri test has not been cleared or approved by the
U.S. Food and Drug Administration. GRAIL’s clinical laboratory is
regulated under CLIA to perform high-complexity testing. The
Galleri test is intended for clinical purposes.
1 Benefits vary by plan. In 2022, the personalized health
screening benefit through GRAIL will be offered to members of AVA
(HMO) 026, AVA (HMO) 027, Balance (PPO) 006, ESRD Balance (HMO
C-SNP) 033, and Platinum (HMO) 008 in California; and AVA (HMO POS)
003 and NC Premier (HMO) 001 in North Carolina.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211206005194/en/
For GRAIL:
Corporate Communications Molly Johnson pr@grail.com
Investor Relations Alex Dobbin ir@grail.com
For Alignment Healthcare:
Priya Shah mPR, Inc. for Alignment Healthcare
alignment@mpublicrelations.com
Alignment Healthcare (NASDAQ:ALHC)
Historical Stock Chart
From Mar 2024 to Mar 2024
Alignment Healthcare (NASDAQ:ALHC)
Historical Stock Chart
From Mar 2023 to Mar 2024